Rein Therapeutics, Inc.
For the period ended Mar 31, 2026. Filed May 15, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 15, 2026
RNTX$0.59-5.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations and Comprehensive Loss
(In thousands, except share and per share data)
| Three Months Ended March 31, | ||
|---|---|---|
| 2026 | 2025 | |
| Revenue | $— | $— |
| Operating expenses: | ||
| Research and development | 3,073 | 3,054 |
| General and administrative | 2,157 | 2,555 |
| Total operating expenses | 5,230 | 5,609 |
| Loss from operations | (5,230) | (5,609) |
| Other (expense) income, net | (608) | 108 |
| Net loss | $(5,838) | $(5,501) |
| Net loss per share—basic and diluted | $(0.19) | $(0.25) |
| Weighted average common shares outstanding—basic and diluted | 30,354,647 | 21,915,891 |
| Comprehensive loss: | ||
| Net loss | $(5,838) | $(5,501) |
| Other comprehensive loss: | ||
| Unrealized loss on investments, net of tax of $0 | — | (45) |
| Foreign currency translation adjustments | — | 31 |
| Total other comprehensive loss | — | (14) |
| Total comprehensive loss | $(5,838) | $(5,515) |
Condensed Consolidated STATEMENT OF CHANGES IN CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ EQUITY
(In thousands, except share data)
| Series X Non-Voting Convertible Preferred Stock · Common Stock · Total Convertible | ||||||||
|---|---|---|---|---|---|---|---|---|
| Shares | Amount | Shares | Amount | Additional Paid-inCapital | AccumulatedOther ComprehensiveLoss | AccumulatedDeficit | Preferred Stock and Stockholders’Equity | |
| Balances at December 31, 2025 | 12,232 | $45,005 | 27,550,222 | $113 | $373,133 | $(62) | $(401,271) | $16,918 |
| Issuance of common stock | — | — | 488,810 | 1 | 354 | — | — | 355 |
| Stock-based compensation expense | — | — | — | — | 156 | — | — | 156 |
| Net loss | — | — | — | — | — | — | (5,838) | (5,838) |
| Balances at March 31, 2026 | 12,232 | $45,005 | 28,039,032 | $114 | $373,643 | $(62) | $(407,109) | $11,591 |
| Balances at December 31, 2024 | 12,232 | $45,005 | 21,666,012 | $108 | $360,697 | $(18) | $(351,400) | $54,392 |
| Issuance of common stock | — | — | 317,772 | — | 738 | — | — | 738 |
| Stock-based compensation expense | — | — | — | — | 264 | — | — | 264 |
| Exercise of stock options | — | — | 21,533 | — | — | — | — | — |
| Unrealized loss on short-term investments | — | — | — | — | — | (45) | — | (45) |
| Foreign currency translation adjustments | — | — | — | — | — | 31 | — | 31 |
| Net loss | — | — | — | — | — | — | (5,501) | (5,501) |
| Balances at March 31, 2025 | $12,232 | $45,005 | $22,005,317 | $108 | $361,699 | $(32) | $(356,901) | $49,879 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.